Boolean network modeling for systematic identification of anticancer drug resistance in colorectal cancer
Pranav Srinivas · 2015
Targeted inhibition of aberrantly activated signaling pathways has proven effective for treatment of many solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer. Unfortunately cancer cells adapt to such monotherapies and eventually develop clinical resistance [1][2]. The drug resistance originates from genetic or epigenetic alterations within cancer cells that enable activation of other growth and survival pathways [3]. Systematic identification and mechanism of drug resistance pathways is desirable for enhancing the efficacy and durability of anticancer drugs. Additionally a comprehensive understanding of drug effecting and resisting pathways can help in the design of multicomponent combination therapies.